Literature DB >> 6505548

Purification and characterization of human neuron-specific enolase: radioimmunoassay development.

S Påhlman, T Esscher, P Bergvall, L Odelstad.   

Abstract

Human neuron-specific enolase, NSE, (E.C.4.2.1.11), has been purified from the brain. The method includes a salt precipitation and column chromatography on DEAE-Sephacel, Sephacryl S-300, DEAE-Sepharose and Blue-Sepharose. The specific activity of the purified NSE was 51 units/mg protein and the yield was 28%. The molecular weight of human NSE was compared to the bovine form purified by the same procedure. On Sephadex G 150 both human and bovine NSE chromatographed, in the dimeric form, as 77,000 Dalton proteins, while the molecular weight of the monomer was 45,000 Daltons as determined by SDS poly-acrylamide gel electrophoresis. An antiserum, specific for NSE, was raised in rabbits and a radioimmunoassay developed. The contribution of lyzed blood cells to the serum NSE levels in eight healthy donors was determined and correlated with the haemoglobin content. Minimal haemolysis can add 5-10 ng NSE/ ml to the true serum level. For accurate serum NSE determinations, serum samples must be free from haemolysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6505548

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  16 in total

1.  Prognosis after cardiac arrest and hypothermia: a new paradigm.

Authors:  Edgar A Samaniego; Suzanne Persoon; Christine A C Wijman
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  Serum neuron-specific enolase level as a biomarker in differential diagnosis of seizure and syncope.

Authors:  Seung-Yeob Lee; Young-Chul Choi; Jeong-Ho Kim; Won-Joo Kim
Journal:  J Neurol       Date:  2010-06-08       Impact factor: 4.849

3.  Neuron-specific enolase (NSE) as a tumour marker and comparative evaluation with carcinoembryonic antigen (CEA) in small-cell lung cancer.

Authors:  I F Adewole; E S Newlands
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

4.  Concentration of neuron-specific enolase and S100 protein in the subretinal fluid of rhegmatogenous retinal detachment.

Authors:  J C Quintyn; F Pereira; M F Hellot; G Brasseur; A Coquerel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-05-20       Impact factor: 3.117

5.  Neurone specific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung.

Authors:  T Esscher; L Steinholtz; J Bergh; E Nöu; K Nilsson; S Påhlman
Journal:  Thorax       Date:  1985-02       Impact factor: 9.139

6.  Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.

Authors:  M van de Pol; A Twijnstra; G P ten Velde; P P Menheere
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Neuron-specific enolase as a marker for intestinal neurons. An immunocytochemical study of the human intestinal tract.

Authors:  T Frykberg; T Esscher; S Påhlman; Y Olsson
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

8.  Neuron specific enolase and serum remain unaffected by ultra high frequency left prefrontal transcranial magnetic stimulation in patients with depression: a preliminary study.

Authors:  Heiko Ullrich; Laura Kranaster; Erich Sigges; Jürgen Andrich; Alexander Sartorius
Journal:  J Neural Transm (Vienna)       Date:  2013-06-05       Impact factor: 3.575

9.  Impact of Admission Time on Treatment and Outcome of Stroke in Patients Admitted to Tertiary Care Hospital: A Pilot Study from Central India.

Authors:  Amit R Nayak; Aliabbas A Husain; Neha H Lande; Anuja P Kawle; Dinesh P Kabra; Girdhar M Taori; Hatim F Daginawala; Rajpal S Kashyap
Journal:  J Clin Diagn Res       Date:  2015-06-01

Review 10.  S-100B and neuron-specific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review.

Authors:  Koichiro Shinozaki; Shigeto Oda; Tomohito Sadahiro; Masataka Nakamura; Yo Hirayama; Ryuzo Abe; Yoshihisa Tateishi; Noriyuki Hattori; Tadanaga Shimada; Hiroyuki Hirasawa
Journal:  Crit Care       Date:  2009-07-22       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.